Mainz, Germany, August 15, 2012 – Reviewing recent developments in the optimization of messenger RNA, TRON scientists document the benefit of improved RNA vectors for gene therapy, immunotherapy and the manipulation of cell fates. The review is up for publication in the journal Current Gene Therapy. Several viral and non-viral vectors have been developed for exogenous protein expression in specific cells. Conventionally, this purpose is achieved through the use of recombinant DNA. Synthetic messenger RNA has emerged as a powerful tool to deliver genetic information that outcompetes DNA for applications that require transient gene expression. The authors summarize current pre-clinical and clinical studies using RNA-based vectors for immunotherapy, T-cell, stem cell and gene therapy including mRNA technology developed at TRON and at Ribological GmbH, a development partner of TRON.